Mapping/NN
of/IN
B-cell/NN
epitopes/NNS
of/IN
the/DT
human/JJ
hepatitis/NN
B/NN
virus/NN
X/NN
protein/NN
./.

The/DT
immune/JJ
response/NN
to/TO
the/DT
X/NN
protein/NN
of/IN
human/JJ
hepatitis/NN
B/NN
virus/NN
(/(
HBV/NN
)/)
was/VBD
studied/VBN
by/IN
epitope/NN
mapping/NN
by/IN
using/VBG
a/DT
set/NN
of/IN
MS2-HBx/NN
fusion/NN
proteins/NNS
and/CC
synthetic/JJ
peptides/NNS
./.
=====
Antibodies/NNS
in/IN
sera/NN
of/IN
patients/NNS
with/IN
acute/JJ
and/CC
chronic/JJ
HBV/NN
infection/NN
showed/VBD
a/DT
multispecific/JJ
immune/JJ
response/NN
./.
=====
Each/DT
serum/NN
contained/VBD
antibodies/NNS
to/TO
a/DT
different/JJ
set/NN
of/IN
epitopes/NNS
,/,
which/WDT
taken/VBN
together/RB
cover/VBP
most/JJS
of/IN
the/DT
HBx/NN
sequence/NN
./.
=====
Some/DT
of/IN
the/DT
epitopes/NNS
were/VBD
detectable/JJ
only/RB
by/IN
immunoblotting/VBG
with/IN
fusion/NN
proteins/NNS
;/:
others/NNS
were/VBD
detectable/JJ
only/RB
by/IN
an/DT
enzyme-linked/JJ
immunosorbent/JJ
assay/NN
(/(
ELISA/NN
)/)
with/IN
synthetic/JJ
peptides/NNS
./.
=====
The/DT
carboxy-terminal/JJ
half/NN
of/IN
the/DT
HBx/NN
protein/NN
was/VBD
preferentially/RB
recognized/VBN
by/IN
antibodies/NNS
from/IN
patients/NNS
with/IN
chronic/JJ
hepatitis/NN
and/CC
contained/VBD
a/DT
short/JJ
immunodominant/JJ
antigenic/JJ
region/NN
with/IN
at/IN
least/JJS
two/CD
major/JJ
nonoverlapping/JJ
epitopes/NNS
./.
=====
Anti-HBx/JJ
antibody/NN
titers/NNS
as/IN
revealed/VBN
by/IN
peptide/NN
ELISAs/NNS
were/VBD
highest/JJS
and/CC
most/RBS
frequent/JJ
in/IN
patients/NNS
with/IN
chronic/JJ
hepatitis/NN
and/CC
usually/RB
low/JJ
in/IN
acutely/RB
infected/JJ
patients/NNS
and/CC
asymptomatic/JJ
carriers/NNS
./.
=====
The/DT
data/NNS
demonstrate/VBP
a/DT
remarkable/JJ
qualitative/JJ
and/CC
quantitative/JJ
heterogeneity/NN
of/IN
the/DT
humoral/JJ
HBx/NN
immune/JJ
response/NN
which/WDT
can/MD
be/VB
monitored/VBN
by/IN
HBx-specific/JJ
peptide/NN
ELISAs/NNS
./.
=====
Such/JJ
tests/NNS
may/MD
become/VB
useful/JJ
diagnostic/JJ
tools/NNS
./.